5T4-Positive CTC Detection via Multi-Marker Fluorescent Staining
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting circulating tumor cells (CTCs) in cancer patients, particularly those expressing the 5T4 antigen, lack integration with standard cytopathologic methods, making it difficult to correlate CTCs with tumor cells from other sites and limiting diagnostic accuracy and treatment efficacy.
Innovation Solution
A method involving the use of multiple markers (DAPI, cytokeratin, CD45, and 5T4 antigen) for identifying and characterizing CTCs through fluorescent labeling and digital microscopy, allowing for detailed imaging and analysis of cell morphology, nuclear-to-cytoplasmic ratios, and apoptotic status, enabling the detection of 5T4-positive CTCs in blood samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If immunocytochemical markers such as EpCam and nuclear staining with DAPI are used to detect CTCs, then CTCs can be enumerated and distinguished, but the correlation with standard morphologic staining is omitted, creating difficulty in comparing CTCs to tumor cells from other sites
Solution Approach 1:
The patent combines immunocytochemical markers (EpCam, 5T4) with standard cytopathologic staining methods (H&E, Papanicolaou) in a single diagnostic workflow. This merging allows CTCs to be detected with high precision while simultaneously maintaining morphologic characterization that correlates with standard pathology practices, thereby resolving the contradiction between detection accuracy and method comparability
Solution Approach 2:
The diagnostic method is designed to serve multiple functions: it detects CTCs using immunocytochemical markers while simultaneously providing morphologic evaluation through standard staining. This multi-functionality enables the same sample to be analyzed for both precise CTC enumeration and comparative morphologic assessment, eliminating the need to choose between specialized and standard methods
2Measurement precision
If multiple markers are used for detailed characterization of CTCs, then diagnostic accuracy and treatment efficacy improve, but the complexity of the detection method increases
Solution Approach 1:
The patent segments the diagnostic process into distinct analytical components: immunocytochemical marker detection (EpCam, 5T4), morphologic evaluation (H&E or Papanicolaou staining), and integrated interpretation. This segmentation allows each component to be optimized independently while maintaining overall diagnostic accuracy, reducing the practical complexity despite using multiple markers
Solution Approach 2:
The patent introduces a standardized interpretation framework that acts as an intermediary between the multiple markers and the final diagnostic conclusion. This mediator integrates the information from EpCam, 5T4, and morphologic features into a unified diagnostic assessment, managing the complexity of multiple markers through systematic interpretation protocols
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables accurate identification and characterization of 5T4-positive CTCs, facilitating early-stage cancer diagnosis, therapy management, and monitoring treatment efficacy, particularly for carcinomas such as colorectal, breast, and non-small cell lung cancers, without the need for cell enrichment.
Implementation Method 1
nuclear staining with DAPI (4',6-diamidino-2-phenylindole), a fluorescent stain that binds strongly to A-T rich regions in DNA
Implementation Method 2
high affinity monoclonal antibodies have been developed that specifically bind to the 5T4 antigen
Data Source
Figure 1A~1B
Figure 2A
Figure 2B
AI summary
Methods are provided for detecting 5T4-positive circulating tumor cells in a mammalian subject. Methods of diagnosing 5T4-positive cancer in a mammalian subject are provided. The methods of detection or diagnosis indicate the presence of 5T4-positive metastatic cancer or early stage 5T4-positive cancer.